A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s94, 2021. DOI: 10.25251/skin.5.supp.94. Disponível em: https://skin.dermsquared.com/skin/article/view/1445. Acesso em: 3 jul. 2025.